Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis by 손주혁
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The OlympiAD Phase III study (NCT02000622) established the clinical benefits of olaparib tablet 
monotherapy (300 mg twice daily) over chemotherapy treatment of physician’s choice (TPC) in 
patients with a germline BRCA1/2 mutation (gBRCAm) and human epidermal growth factor receptor 2 
(HER2)-negative metastatic breast cancer who had received ≤2 chemotherapy lines in the metastatic 
setting. Here, we report pre-specified analyses of data from Asian (China, Japan, Korea and Taiwan) 
patients in the study. All patients were randomized 2:1 to olaparib tablets (300 mg twice daily) or 
single-agent chemotherapy TPC (21-day cycles of either capecitabine, eribulin or vinorelbine). The 
primary endpoint was progression-free survival assessed by blinded independent central review. 
The prevalence of gBRCAm in the OlympiAD Asian subgroup screened for study recruitment was 
13.5%. Patient demographics and disease characteristics of the Asian subgroup (87/302 patients) 
were generally well balanced between treatment arms. Asian patients in the olaparib arm achieved 
longer median progression-free survival, assessed by blinded independent central review, versus the 
chemotherapy TPC arm (5.7 vs 4.2 months; HR = 0.53 [95% CI: 0.29–0.97]), which was consistent with 
findings in the global OlympiAD study population. Findings on secondary efficacy and safety/tolerability 
outcome measures in Asian patients were also similar to those observed in the global OlympiAD 
study population. The OlympiAD study was not powered to detect race-related differences between 
treatment groups; however, the consistency of our findings with the global OlympiAD study population 
suggests that previously reported findings are generalizable to Asian patients.
Over the last few decades there has been a dramatic increase in the incidence of breast cancer (BC), the most 
prevalent cancer in Asian females1, among Asian populations2,3. However, the predominance of Western patients 
in some BC clinical trials raises potential concerns over the generalizability of their findings with respect to effec-
tive disease management in routine clinical practice to racially diverse populations, including Asian patients2,4.
This is of particular importance because multiple differences exist between Asian and Western patient popula-
tions (in their genetic background, socioeconomic status, lifestyle, culture and health beliefs/behaviours) that play 
1Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, 
Korea. 2National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical 
Sciences and Peking Union Medical College, Beijing, China. 3The First Hospital of Jilin University, Changchun, China. 
4Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5Medical Oncology Center, Hunan Tumor Hospital, 
Changsha, China. 6Cheng Ching Hospital, Taichung City, Taiwan. 7Department of Breast Oncology, Aichi Cancer 
Center Hospital, Aichi, Japan. 8Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 
Korea. 9Yonsei University College of Medicine, Seoul, Korea. 10Taipei Veterans General Hospital, National Yang-Ming 
University, Taipei, Taiwan. 11AstraZeneca, Gaithersburg, MD, USA. 12National Hospital Organization, Osaka National 
Hospital, Osaka, Japan. ✉e-mail: moisa@snu.ac.kr
open
2Scientific RepoRtS |         (2020) 10:8753  | https://doi.org/10.1038/s41598-020-63033-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
an important role in dictating BC incidence and influencing prognosis. For example, with regard to genetic back-
ground, Asian patients develop BC at a younger age in comparison to Western patients, therefore the influence of 
BRCA1 and BRCA2 (BRCA1/2) mutations in Asian patients are expected to be different than in Western patients1. 
Therefore, BC clinical trials generating data specific to Asian patients with BC are of considerable interest2,5.
Olaparib is a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor that has shown clinical efficacy as 
monotherapy in ovarian, breast and other solid tumour types6–8. Previously reported findings from the Phase III 
OlympiAD trial demonstrated a significant improvement in progression-free survival (PFS) with olaparib tablet 
monotherapy versus chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA1/2 
mutation (gBRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metastatic BC (mBC)9. 
Thus far, outcome measures evaluated in the OlympiAD trial have not been explored to determine the consistency 
of the clinical benefits of olaparib monotherapy between the global study population (Europe, North America 
and South America) and a subgroup of Asian patients. To this end, we report pre-specified subgroup analyses to 
determine the efficacy and safety of olaparib monotherapy versus chemotherapy TPC in the Asian (China, Japan, 
Korea and Taiwan) subpopulation compared with the global OlympiAD study population.
Methods
Only a brief overview of the methodology used in the OlympiAD study will be provided here given that full 
details have been reported previously9.
Study design and patient eligibility. This was a Phase III, multicentre, international, randomized, con-
trolled, open-label study (Clinical trial registration number NCT02000622; 04/12/2013) in adults with BC who 
met the following key eligibility criteria: (1) triple-negative or HER2-negative and hormone-receptor-positive 
mBC;(2) deleterious or suspected deleterious gBRCAm that was confirmed via central testing with the 
BRACAnalysis CDx® test (Myriad Genetics, Inc); (3) received ≤2 previous chemotherapy regimens for meta-
static disease, as well as prior anthracycline (unless contraindicated) and a taxane in the adjuvant, neoadjuvant 
or metastatic setting; (4) if hormone receptor-positive BC, then the patient had received ≥1 endocrine therapy 
(either adjuvant or metastatic setting) and disease had progressed on therapy, unless the patient was considered 
ineligible for endocrine treatment. Patients were included regardless of previous platinum-based therapy for BC, 
but only if their disease had not progressed while receiving that treatment.
Informed consent was provided by all patients who participated in the study and the protocol was approved by 
the Seoul National University Hospital (EC) Institutional Review Board. The study was performed in accordance 
with the Declaration of Helsinki, Good Clinical Practice guidelines and the AstraZeneca policy on bioethics.
Randomization and study treatments. Eligible patients were randomized using an interactive voice or Web 
response system at centres in China, Japan, Korea and Taiwan in a 2:1 ratio to either olaparib monotherapy (300 mg 
twice daily [bid]; tablets) or predeclared single-agent chemotherapy TPC (capecitabine, eribulin or vinorelbine [21-day 
cycles]). In China, only capecitabine or vinorelbine were considered in the chemotherapy TPC arm because eribulin did 
not have regulatory approval at that time. Study treatment was continued until patients’ disease progressed or unaccept-
able side effects were experienced. Crossover from chemotherapy TPC to olaparib within the study was not allowed.
Study endpoints and assessments. Findings on the primary endpoint, PFS by blinded independent central 
review (BICR; modified Response Evaluation Criteria in Solid Tumors version 1.1 criteria), and secondary endpoints 
in the OlympiAD study have been reported previously9. Secondary endpoints included time to second progression 
or death (PFS2), overall survival (OS), objective response rate (ORR), and safety and tolerability. Computed tomog-
raphy or magnetic resonance imaging were used to assess tumours. Reported adverse events (AEs) were graded 
using the National Cancer Institute’s Common Terminology Criteria for Adverse Events version 4.0.
Statistical analysis. To consider consistency of treatment effect across potential or expected prognostic 
factors, the OlympiAD study design incorporated several predefined subgroup analyses, including geographical 
region (Asia, Europe, North America and South America). The Asian subgroup included patients from China, 
Japan, Korea and Taiwan.
Efficacy analyses were conducted using the full analysis set, whereas the safety analysis set included all patients 
who had received ≥1 dose of study treatment. The Kaplan–Meier method was used to generate time-to-event 
curves, from which medians were calculated. For analyses of survival (PFS, PFS2 and OS) in Asian patients, the 
hazard ratios (HRs) and associated 95% confidence intervals (CIs) were estimated using an unstratified log-rank 
test. A HR of <1 favoured olaparib 300 mg bid over chemotherapy TPC.
Ethical approval/informed consent. The institutional review boards or independent ethics committees 
of all investigational sites approved the protocol. The study was performed in accordance with the Declaration 
of Helsinki, Good Clinical Practice, and the AstraZeneca policy on bioethics10. Informed consent was provided 
by all patients who participated in the study and the protocol was approved by the Seoul National University 
Hospital (EC) Institutional Review Board and the ethics review committees at the participating institutions.
Results
Asian patients in the olympiAD study. Among patients with unknown BRCA status who were screened 
for the OlympiAD study using a central Myriad test, the prevalence of a deleterious or suspected deleterious BRCA 
mutation was 13.5% (121/895) in Asian patients (BRCA1, 54/121 [44.6%]; BRCA2 64/121 [52.9%]; both BRCA1 
and BRCA2 3/121 [2.5%]) compared with 11.4% (101/888; BRCA1, 58/101 [57.4%]; BRCA2 43/101 [42.6%]) in 
Caucasian patients, and 10.4% (14/135; BRCA1, 8/14 [57.1%]; BRCA2 6/14 [42.9%]) in ‘other’ patients.
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A total of 302 patients between 7 April 2014 and 27 November 2015 were randomized to olaparib 300 mg bid 
tablet monotherapy (n = 205) or chemotherapy TPC (n = 97), which included a subgroup of 87 Asian patients 
(Supplementary Fig. 1). Within the Asian subgroup, 59 and 28 patients were allocated to the olaparib and chemo-
therapy TPC arms, respectively. One Asian patient declined study treatment because of their allocation to the 
chemotherapy TPC arm. Patient demographics and disease characteristics of the Asian subgroup were generally 
well balanced between treatment arms (Table 1). Each of the treatment arms comprised patients from China, 
Japan, Korea and Taiwan; among olaparib recipients, 32 (54.2%) patients were from China, 15 (25.4%) were from 
Japan, 11 (18.6%) were from Korea, and one (1.7%) was from Taiwan, and for patients receiving chemotherapy 
TPC, nine (32.1%) patients each were from China, Japan and Korea, and one patient (3.6%) was from Taiwan.
Efficacy. PFS. Asian patients in the olaparib arm achieved longer median PFS compared with the chemo-
therapy TPC arm (5.7 vs 4.2 months; HR = 0.53 [95% CI: 0.29–0.97]; data maturity 77%), as assessed by BICR 
(Fig. 1). This BICR-assessed PFS benefit of olaparib over chemotherapy TPC in the Asian subgroup was con-
sistent with that observed in the global OlympiAD study population (7.0 vs 4.2 months; HR = 0.58 [95% CI: 
0.43–0.80])9. Furthermore, the improvement in BICR-assessed PFS associated with olaparib was supported by 
investigator-assessed PFS (8.3 vs 4.1 months; HR = 0.29 [95% CI: 0.16–0.55]; data maturity 80%) (Fig. 2).
PFS2, OS and ORR. Asian patients in the olaparib arm also achieved a longer median time to PFS2 compared 
with chemotherapy TPC (12.4 vs 8.6 months; HR = 0.43 [95% CI: 0.22–0.84]; data maturity 57%) (Fig. 3). In the 
Asian subgroup analysis, at the time of the data cut-off for the final OS analysis, median OS was similar in the 
olaparib and chemotherapy TPC arms (20.5 vs 20.9 months; HR = 0.98 [95% CI: 0.54–1.78]; data maturity 56.3%; 
median follow-up was 19.3 and 18.4 months for the olaparib and chemotherapy TPC arms, respectively) (Fig. 4).
ORR was higher for evaluable Asian patients in the olaparib arm (63.6% [95% CI: 47.8–77.6]) than in the 
chemotherapy TPC arm (38.1% [95% CI: 18.1–61.6]). Higher rates of BICR-assessed complete response and par-
tial response were reported among Asian patients in the olaparib arm versus the chemotherapy TPC arm (1.7% vs 
0% and 47.5% vs 28.6%, respectively). A best objective response of stable disease lasting ≥11 weeks was achieved 
by 30.5% and 25.0% of Asian patients in the olaparib and chemotherapy TPC arms, respectively.
Moreover, Asian patients showed a longer median (interquartile range) duration of response with olaparib 
versus chemotherapy TPC (4.2 [2.8–8.2] vs 2.8 months [2.1–12.2]). In the Asian subgroup, median (interquartile 
range) time to onset of response was similar in each treatment arm (olaparib, 1.5 months [1.4–2.8]; chemotherapy 
TPC, 1.5 months [1.3–2.8]).
Safety and tolerability. Median (range) duration of treatment in OlympiAD Asian patients was longer 
in the olaparib arm compared with the chemotherapy TPC arm (253 [14–1103] vs 91 [21–385] days). Median 









Median age, years (range) 46.0 (28–74) 47.0 (24–66) 44.0 (22–76) 45.0 (24–68)
Median body weight, kg (range) 59.0 (36–85) 55.5 (39–86) 64.0 (36–113) 62.0 (39–112)
Male, n (%) 1 (1.7) 1 (3.6) 5 (2.4) 2 (2.1)











































Prior chemotherapy for mBC, n (%) 41 (69.5) 23 (82.1) 146 (71.2) 69 (71.1)
Prior platinum treatment, n (%) 21 (35.6) 8 (28.6) 60 (29.3) 26 (26.8)










Table 1. Patient demographics and disease characteristics of the Asian subgroup and the global OlympiAD 
study population. Data cut-off 9 December 2016; *BRCA mutation confirmed using BRACAnalysis CDx® 
(Myriad Genetic Laboratories, Inc); †Six patients did not receive study treatment in the global population, one 
of whom was in the Asian subgroup. No patients in China received eribulin as chemotherapy TPC because it did 
not have regulatory approval in that country. BRCAm, BRCA mutation; ECOG, Eastern Cooperative Oncology 
Group; ER+, oestrogen receptor positive; NA, not applicable; PR+, progesterone receptor positive; TNBC, 
triple-negative breast cancer; TPC, treatment of physician’s choice.
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relative dose intensity in the Asian subgroup was 99.4% and 93.6% in the olaparib and chemotherapy TPC arms, 
respectively.
The safety and tolerability profile of olaparib in Asian patients was broadly consistent with that reported pre-
viously in the global OlympiAD study population (Table 2). In the olaparib arm, nausea and anaemia were the 
most commonly reported AEs among Asian patients (54.2% and 44.1%, respectively) and the global OlympiAD 
study population (58.0% and 40.0%, respectively). AEs reported more frequently in the olaparib arm by Asian 
patients than in the global OlympiAD study population (>10% difference between subgroup and global popu-
lation) were decreased white blood cell (WBC) count (39.0% vs 16.1%, respectively) and elevated transaminase 
levels (increased alanine aminotransferase, 27.1% vs 11.7%; increased aspartate aminotransferase, 22.0% vs 9.8%). 
In the olaparib arm, AEs reported less frequently by Asian patients versus the global OlympiAD study popula-
tion (>10% difference between subgroup and global population) were neutropenia (8.5% vs 27.3%) and fatigue 
(16.9% vs 29.8%). Diarrhoea in the olaparib arm was reported by 15.3% and 20.5% of Asian patients and the 
global OlympiAD study population, respectively.
The incidence of grade ≥3 AEs in Asian patients (olaparib, 45.8%; chemotherapy TPC, 59.3%) was similar to 
that in the global OlympiAD study population (olaparib, 38.0%; chemotherapy TPC, 49.5%) (Table 2). The most 
commonly reported grade ≥3 AE in the olaparib arm among Asian patients and the global OlympiAD study pop-
ulation was anaemia (20.3% and 16.1%, respectively). A total of 8 (13.6%) and 2 (7.4%) Asian patients receiving 
Figure 1. PFS (as determined by BICR) in the olaparib and chemotherapy TPC arms in the Asian subgroup and 
global OlympiAD study population. Data cut-off 9 December 2016; PFS data maturity, 77% (67/87 patients). 
BICR, blinded independent central review; bid, twice daily; CI, confidence interval; HR, hazard ratio; PFS, 
progression-free survival; TPC, treatment of physician’s choice.
Figure 2. PFS (as determined by investigator assessment) in the olaparib and chemotherapy TPC arms in the 
Asian subgroup. Data cut-off 9 December 2016; PFS data maturity, 80% (70/87 patients). Median time from 
randomization to censoring (censored patients only): 11.1 months olaparib and 4.4 months chemotherapy. 
bid, twice daily; CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; TPC, treatment of 
physician’s choice.
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olaparib or chemotherapy TPC, respectively, received blood transfusions and in the global OlympiAD study 
population, 37 (18.0%) and 5 (5.5%) patients received blood transfusions, respectively. In the olaparib arm, grade 
≥3 AEs of decreased WBC count were more commonly reported in Asian patients than in the global OlympiAD 
study population (10.2% vs 3.4%), whereas grade ≥3 neutropenia was less commonly reported (1.7% vs 9.3%).
In the olaparib arm, the proportions of Asian patients who experienced dose reduction, treatment interrup-
tion/delay, or treatment discontinuation due to AEs (16.9%, 28.8%, and 6.8%, respectively) were similar to those 
in the global OlympiAD study population (25.4%, 36.1%, and 4.9%, respectively) (Table 2). AEs leading to treat-
ment discontinuation among Asian patients in the olaparib arm included anaemia (n = 3), increased intracranial 
pressure (n = 1), and decreased platelet count (n = 1). In the chemotherapy TPC arm, AEs of anaemia (n = 1) and 
decreased neutrophil count (n = 1) led to treatment discontinuation in Asian patients. There were no incidences 
of acute myeloid leukaemia, myelodysplastic syndromes, or pneumonitis reported in Asian patients or the global 
OlympiAD study population in either treatment arm (one patient in the global OlympiAD study population 
reported an AE of pneumonitis which was subsequently confirmed to be misdiagnosed as pneumonitis and was 
actually related to disease progression). No Asian patient died as the result of an AE in either treatment arm of 
the OlympiAD study.
Discussion
Approximately 29% of patients in the global OlympiAD study population were Asian. The prevalence of gBRCAm 
in Asian patients screened for recruitment into the OlympiAD study (13.5%) is consistent with that across other 
studies of Asian patients with BC (familial BC, 8.0–31.8%; early-onset BC, 2.8–21.4%)1. These rates are high 
and warrant increased awareness of, and screening for, BRCA1/2 mutations among Asian populations. Notably, 
Figure 3. PFS2 (as determined by investigator assessment) in the olaparib and chemotherapy TPC arms in the 
Asian subgroup. Data cut-off 9 December 2016; PFS2 data maturity, 57% (50/87 patients). bid, twice daily; CI, 
confidence interval; HR, hazard ratio; PFS2, time to second progression or death; TPC, treatment of physician’s 
choice.
Figure 4. OS in the olaparib and chemotherapy TPC arms in the Asian subgroup. Data cut-off 25 September 
2017; OS data maturity, 56% (34/87 patients). bid, twice daily; CI, confidence interval; HR, hazard ratio; OS, 
global survival; TPC, treatment of physician’s choice.
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researchers conducting a whole-exome and whole-transcriptome profiling study identified not only higher fre-
quencies of BRCA1/2 mutation in younger Korean patients with BC tumours, but also enrichment of a mutation 
signature linked to homologous recombination repair (HRR) deficiency in triple-negative BC (TNBC)11. Their 
findings suggested that PARP inhibitors may prove to be a particularly potent therapeutic intervention among 
younger Asian patients with TNBC.
In general, the baseline characteristics (age, gender, ECOG performance status and hormone receptor status) 
were generally well balanced between treatment arms and between the Asian subgroup and the global population. 
In the Asian subgroup, fewer patients receiving olaparib had received prior chemotherapy for mBC compared 
with those receiving chemotherapy TPC (70 vs 82%). The BRCA1/2 mutation status was also slightly different 
in the Asian subgroup between treatment groups with more patients receiving olaparib treatment harbouring a 
BRCA1 mutation (53 vs 43% for chemotherapy TPC), and conversely more patients receiving chemotherapy TPC 
had a BRCA2 mutation (57 vs 42% for olaparib); subgroup analyses of PFS in the global OlympiAD study popula-
tion showed that the type of BRCA mutation did not appear to influence the benefit of olaparib treatment9. When 
compared with the global study population, Asian patients in both treatment arms had a lower median body 
weight, and a greater number of Asian patients in the chemotherapy TPC arm had received prior chemotherapy 
for metastatic disease (82%) compared with the global population (71%). There was also a difference between the 
Asian and global populations in the type of chemotherapy patients received during the study with Asian patients 
more likely to receive eribulin (43%) than the global population (35%), whereas in the global population the most 
common type of chemotherapy received was capecitabine (42% vs 36% for Asian patients).
Findings from our pre-specified analyses suggested that the BICR-assessed PFS benefit achieved by Asian 
patients in the olaparib arm compared with those in the chemotherapy TPC arm was consistent with the previ-
ously reported primary endpoint in the global OlympiAD study population9. This effect was further substantiated 
by the investigator-assessed PFS benefit of olaparib over chemotherapy TPC in the Asian subgroup, which was, 
again, consistent with that observed in the global OlympiAD study population (7.8 vs 3.8 months; HR = 0.50 
[95% CI: 0.36–0.68]; P < 0.001)9. The slight imbalances in the baseline characteristics between the Asian sub-
group treatment arms and between the Asian and global populations do not appear to have had any meaningful 
effect on the BICR or investigator-assessed PFS results.
Asian subgroup Global OlympiAD study population
Olaparib (N = 59) Chemotherapy TPC (N = 27) Olaparib (N = 205) Chemotherapy TPC (N = 91)
Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3
Any AE 59 (100) 27 (45.8) 26 (96.3) 16 (59.3) 200 (97.6) 78 (38) 87 (95.6) 45 (49.5)
Nausea 32 (54.2) 0 11 (40.7) 0 119 (58.0) 0 32 (35.2) 1 (1.1)
Anaemia† 26 (44.1) 12 (20.3) 9 (33.3) 4 (14.8) 82 (40.0) 33 (16.1) 24 (26.4) 4 (4.4)
Neutropenia‡ 5 (8.5) 1 (1.7) 7 (25.9) 4 (14.8) 56 (27.3) 19 (9.3) 45 (49.5) 24 (26.4)
Decreased WBC count 23 (39.0) 6 (10.2) 14 (51.9) 8 (29.6) 33 (16.1) 7 (3.4) 19 (20.9) 9 (9.9)
Vomiting 17 (28.8) 0 6 (22.2) 0 66 (32.2) 0 14 (15.4) 1 (1.1)
Increased ALT 16 (27.1) 1 (1.7) 7 (25.9) 1 (3.7) 24 (11.7) 3 (1.5) 16 (17.6) 1 (1.1)
Increased AST 13 (22.0) 2 (3.4) 8 (29.6) 0 20 (9.8) 5 (2.4) 15 (16.5) 0
Decreased appetite 11 (18.6) 0 7 (25.9) 0 35 (17.1) 0 11 (12.1) 0
Upper respiratory tract 
infection 10 (16.9) 1 (1.7) 6 (22.2) 0 27 (13.2) 1 (0.5) 9 (9.9) 0
Fatigue 10 (16.9) 0 1 (3.7) 0 61 (29.8) 7 (3.4) 22 (24.2) 1 (1.1)
Diarrhoea 9 (15.3) 0 6 (22.2) 0 42 (20.5) 1 (0.5) 20 (22.0) 0
Pyrexia 8 (13.6) 0 6 (22.2) 0 30 (14.6) 0 16 (17.6) 0
Headache 7 (11.9) 0 4 (14.8) 1 (3.7) 42 (20.5) 2 (1.0) 14 (15.4) 2 (2.2)
PPE syndrome 1 (1.7) 0 5 (18.5) 1 (3.7) 1 (0.5) 0 19 (20.9) 2 (2.2)
Dose reduction due to 
AEs, n (%) 10 (16.9) — 8 (29.6) — 52 (25.4) — 28 (30.8) —
Treatment interruption 
due to AEs, n (%) 17 (28.8) — 6 (22.2) — 74 (36.1) — 26 (28.6) —
Treatment 
discontinuations because 
of AEs, n (%)
4 (6.8) — 2 (7.4) — 10 (4.9) — 7 (7.7) —
Table 2. Summary of AEs in the Asian subgroup and the global OlympiAD study population. Most common 
AE of any grade occurring in ≥20% of Asian patients or the global OlympiAD study population in either 
treatment arm. AEs were graded using the National Cancer Institute’s Common Terminology Criteria for 
Adverse Events version 4.0, and data were collected for the duration of study and the 30-day post-treatment 
follow-up period. Data cut-off 25 September 2017; †Anaemia includes anaemia, decreased haemoglobin 
level, decreased haematocrit, decreased red blood cell count and erythropenia; ‡Neutropenia includes febrile 
neutropenia, granulocytopenia, decreased granulocyte count, neutropenia, neutropenic sepsis, decreased 
neutrophil count and neutropenic infection. AE, adverse event; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; PPE, palmar–plantar erythrodysesthesia; WBC, white blood cell.
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The maintenance of benefit beyond first progression for olaparib compared with chemotherapy TPC was 
supported by PFS2 findings in the Asian subgroup that reflected those observed in the global OlympiAD study 
population (13.2 vs 9.3 months; HR = 0.57 [95% CI: 0.40–0.83]; P = 0.003)9. The continued benefit of olaparib 
following initial progression demonstrates that olaparib does not affect the efficacy of subsequent treatments. 
Antitumour activity findings in Asian patients suggested an advantage of olaparib over chemotherapy TPC that 
was consistent with that reported in the global OlympiAD study population in terms of not only ORR (59.9% 
[95% CI: 52.0–67.4] vs 28.8% [95% CI:18.3–41.3]), but also median duration of response (6.4 [2.8–9.7] vs 7.1 
months [3.2–12.2])9. Furthermore, in line with the global OlympiAD study population, there was no delay in the 
time to response for Asian patients receiving olaparib compared with those receiving chemotherapy TPC with 
the median time to onset of response being 1.5 months in both arms; this finding is an important consideration 
for symptomatic or rapidly progressing patients.
Our results showed that the safety and tolerability profile of olaparib in Asian patients was generally similar to 
that reported previously in the global OlympiAD study population9, suggesting that the slight imbalances in the 
baseline characteristics between treatment arms for the Asian subgroups has not impacted the safety of olaparib 
in these patients. Asian patients had a longer median duration of treatment in the olaparib arm compared with 
the chemotherapy TPC arm with a high relative dose intensity (olaparib arm, 99.4%; chemotherapy TPC, 93.6%). 
It has been proposed that there may be race-related differences in tolerability and response to anticancer drugs 
in patients with BC12. For example, findings from a retrospective database review of patients with early-stage 
BC suggested that Asian patients receiving adjuvant doublet therapy (docetaxel plus cyclophosphamide) had a 
higher liability for grade ≥3 neutropenia compared with their Western counterparts (>30% vs 4%)13. Our data 
showed less marked contrasts in incidences of grade ≥3 AEs between Asian patients and the global OlympiAD 
study population. In the olaparib arm, the greatest contrasts in incidence of grade ≥3 AEs between Asian patients 
and the global OlympiAD study population were for decreased WBC count (10.2% vs 3.4%), although neutro-
penia was not more frequent in Asian patients (1.7% vs 9.3% in the global population). Additionally, there were 
no reports of febrile neutropenia in either Asian patients or those from the global OlympiAD study population 
receiving olaparib.
The finding of similar efficacy and safety in Asian and global study populations was not unexpected as the 
pharmacokinetics of olaparib tablets have been reported to be similar between Asian and Western patients14. 
The consistency of findings supports similar clinical benefits of olaparib tablet monotherapy over chemotherapy 
TPC in patients with a gBRCAm and HER2-negative mBC in Asian patients and the global OlympiAD study 
population.
A review addressing future needs for Asian BC research prioritized diagnostic and prognostic studies and 
called for the recruitment of patients from various Asian settings into international clinical trials to advance 
understanding of the effectiveness of novel therapeutic interventions in this subpopulation2. The OlympiAD 
study is a step towards addressing this need by recruiting a substantial proportion of Asian patients (~29%).
conclusions
Findings from these pre-specified analyses demonstrated a greater clinical benefit in Asian patients for olaparib 
tablet monotherapy compared with chemotherapy TPC. This clinical benefit observed in Asian patients is con-
sistent with that reported in the global OlympiAD study population, as measured by BICR-assessed PFS (the 
primary endpoint) and investigator-assessed PFS, PFS2 and ORR. Olaparib was generally well tolerated in Asian 
patients and was characterized by low discontinuation rates as a result of toxicity, as well as a lower rate of grade 
≥3 AEs compared with chemotherapy TPC. The safety profile of olaparib in the Asian subpopulation was broadly 
consistent with that observed in the global OlympiAD study population.
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